Skip to main content
Gregory Verghese

Gregory Verghese

CTO of PharosAI

Biography

Gregory Verghese is CTO of PharosAI, a venture focused on democratising access to multimodal cancer datasets, where he leads the engineering, data science, and AI teams. An early-career researcher with a background in physics and computer science, he is undertaking a PhD at King's College London under Professor Anita Grigoriadis and Dr Christopher Banerji focused on developing transparent and explainable deep learning techniques for computational pathology and clinical AI.

Research

Grigoriadis Cancer Bioinformatics

The Grigoriadis Cancer Bioinformatics group is exploring molecular determinants at the primary tumour site and in the draining lymph nodes, mainly in triple negative breast cancers.

News

PharosAI wins funding to develop AI models that could create 'digital twins' of human tissue

PharosAI, a collaboration led by several academic institutions and NHS partners, has received funding from Innovate UK to develop advanced AI models capable...

Artificial Intelligence Computing Data AdobeStock_200146313(1)

Features

Building cyber security into the foundations of PharosAI's innovative platform for cancer care

PharosAI partners with Synoptix to embed secure engineering, cyber risk management and operational resilience into its AI-powered platform for cancer research...

Research

Grigoriadis Cancer Bioinformatics

The Grigoriadis Cancer Bioinformatics group is exploring molecular determinants at the primary tumour site and in the draining lymph nodes, mainly in triple negative breast cancers.

News

PharosAI wins funding to develop AI models that could create 'digital twins' of human tissue

PharosAI, a collaboration led by several academic institutions and NHS partners, has received funding from Innovate UK to develop advanced AI models capable...

Artificial Intelligence Computing Data AdobeStock_200146313(1)

Features

Building cyber security into the foundations of PharosAI's innovative platform for cancer care

PharosAI partners with Synoptix to embed secure engineering, cyber risk management and operational resilience into its AI-powered platform for cancer research...